Investing Port

P/S	177.06
P/BV	22.13
EV/EBITDA	-19.06
EBITDA	-0.05
Цена ао	21.02

		Недооценка Название Значение Оценка P/S 177.06 1 P/BV 22.13 1 P/E 0 EV/EBITDA -19.06 10	Эффективность Название Значение Оценка ROA, % -27.72 1 ROE, % -90.46 1
	Дивиденды Название Значение Оценка Div yield, % 0 DSI 0 0	Долг Название Значение Оценка Долг/EBITDA 0	Импульс роста Название Значение Оценка Рост прибыли, % 41.42 8 Рост цены акции, % -89.28 0 Рост дивидендов, % 0 0

Institutions	Объем	Доля, %
Alambic Investment Management, L.P.	59766	0.12
AdvisorShares Investments, LLC	2600	0.01
Samsara BioCapital, LLC	2153265	4.26
Telemetry Investments, L.L.C.	267466	0.53
Foresite Capital Management III, LLC	684912	1.36
Parkman Healthcare Partners LLC	1842661	3.65
Endurant Capital Management LP	1432817	2.84
SEI Investments Management Corp	141371	0.28
BMO Global Asset Management	75944	0.15
Aisling Capital Management LP	634455	1.26
Sofinnova Ventures	1911573	3.78
EcoR1 Capital, LLC	1531312	3.03
BlackRock Fund Advisors	1353400	2.68
Vivo Capital, LLC	1647214	3.26
Rock Springs Capital Management LP	2076307	4.11
LoCorr Fund Management, LLC	3773	0.01
M & G Investment Management	40645	0.08
Invesco Capital Management LLC	121038	0.24
The Variable Annuity Life Insurance Company	119846	0.24
Foresite Capital Management IV, LLC	144874	0.29

ETF	Доля, %	Доходность за год, %
AdvisorShares Dorsey Wright Micro-Cap ETF	1.51	61.20

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK\u002FTXK\u002FJAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.